The aim of our study was to evaluate functional alterations of the corpus cavernusum and its correlation with the lack of response to treatment with PDE5i in eugonadal patients with Type 2 Diabetes Mellitus and Erectile Dysfunction. In this prospective randomized study we included 157 patients. All were treated with 5 mg tadalafil daily and 100 mg sildenafil on demand and the response to treatment was assessed in 6 month by dividing them into 2 groups: G1: Good response. Significative improvement of erectile function according to IIEF-5, and G2: There was not an improvement with the treatment. At the end of the treatment we performed neurological and vascular studies to both groups. Also we performed CC-EMG in order to evaluate penile autonomic neuropathy. 82 patients were included in G1 and 75 in G2. The time evolution of the ED was 1.5 years for G1 and 5 years for G2. Average fasting glucose and glycosilated hemoglobin values were significantly higher in G2 than in G1. Also we observed significant differences in penile vascular parameters between both groups. Peripheral neuropathy parameters did not show differences between both groups. Cavernous smooth muscle electromyography showed asynchronous and asymetric potentials in G1 (minimal autonomic neuropathy) and denervation potentials in G2 characteristic of severe CC damage. It is concluded that vascular and autonomic alterations are causes of severe CC damage and lack of response to treatment with PDE5i in this population. Peripheral neuropathy is not part of this process.
Phé, V. and Rouprêt, M. (2012) Erectile Dysfunction and Diabetes: A Review of the Current Evidence-Based Medicine and a Synthesis of the Main Available Therapies. Diabetes & Metabolism, 38, 1-13.
De Berardis, G., Francioisi, M., Belfiglio, M., Di Nardo, B., Greenfield, S., Kaplan, S.H., Pellegrini, F., Sacco, M., Tognoni, G., Valentini, M. and Nicolucci, A., Quality of Care and Outcomes in Type 2 Diabetes (QuED) Study Group (2002) Erectile Dysfunction and Quality of Life in Tipe 2 Diabetic Patients: A Serious Problem Too Often Overlooked. Diabetes Care, 25, 284-291. http://dx.doi.org/10.2337/diacare.25.2.284
Lewis, R.W., Fugl-Meyer, K.S., Corona, G., Hayes, R.D., Laumann, E.O., Moreira Jr., E.D., Rellini, A.H. and Segraves, T. (2010) Definitions/Epidemiology/Risk Factors for Sexual Dysfunction. The Journal of Sexual Medicine, 7, 1598-1607. http://dx.doi.org/10.1111/j.1743-6109.2010.01778.x
Kapur, V., Chien, C.V., Fuess, J.E. and Schwarz, E.R. (2008) The Relationship between Erectile Dysfunction and Cardiovascular Disease. Part II: The Role of PDE-5 Inhibition in Sexual Dysfunction and Cardiovascular Disease. Reviews in Cardiovascular Medicine, 9, 187-95.
Nehra, A. (2009) Erectile Dysfunction and Cardiovascular Disease: Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors in Men with Both Conditions. Mayo Clinic Proceedings, 84, 139-148. http://dx.doi.org/10.4065/84.2.139
Awad, H., Salem, A., Gadalla, A., El Wafa, N.A. and Mohamed, O.A. (2010) Erectile Function in Men with Diabetes Type 2: Correlation with Glycemic Control. International Journal of Impotence Research, 22, 36-39.
Deyoung, L., Chung, E., Lovar, J.R., Romano, W. and Brock, G.B. (2012) Daily Use of Sildenafil Improves Endothelial Function in Men with Type 2 Diabetes. Journal of Andrology, 33, 176-80.
Yang, M., Sontaq, A., Litman, H.J. and Rosen, R.C. (2013) Non Responders, Partial Responders and Complete Responders to PDE5 Inhibitors Therapy according to IIEF Criteria. Validation of an Author-Based Treatment Responder Classification. The Journal of Sexual Medicine, 10, 3029-3037. http://dx.doi.org/10.1111/jsm.12335
Fugl-Meyer, A.R., Lodnert, G., Bränholm, I.B. and Fugl-Meyer, K.S. (1997) On Life Satisfaction in Male Erectile Dysfunction. International Journal of Impotence Research, 9, 141-148. http://dx.doi.org/10.1038/sj.ijir.3900269
Hatzimouratidis, K. and Hatzichristou, D. (2014) How to Treat Erectile Dysfunction in Men with Diabetes: From Pathophysiology to Treatment. Current Diabetes Reports, 14, 545. http://dx.doi.org/10.1007/s11892-014-0545-6
Martin-Morales, A., Sanchez-Cruz, J.J., Saenz de Tejada, I., Rodriguez-Vela, L., Jimenez-Cruz, J.F. and Burgos-Rodriguez, R. (2001) Prevalence and Independent Risk Factors for Erectile Dysfunction in Spain: Results of the Epidemiologystudy. The Journal of Urology, 166, 569-575. http://dx.doi.org/10.1016/S0022-5347(05)65986-1
O’Donnell, A.B., Araujo, A.B. and McKinlay, J.B. (2004) The Health of Normally Agingmen: The Massachusetts Male Aging Study (1987-2004). Experimental Gerontology, 39, 975-984.
Fonseca, V., Seftel, A., Denne, J. and Fredlund, P. (2004) Impact of Diabetes Mellitus on the Severity of Erectile Dysfunction and Response to Treatment: Analysis of Data from Tadalafil Clinical Trials. Diabetologia, 4, 1914-1923.
Dunsmuir, W. and Holmes, S. (1996) Theaetiology and Management of Erectile, Eyaculatory and Fertility Problems in Men with Diabetes Mellitus. Diabetic Medicine, 13, 700-708.
Cellek, S., Cameron, N.E., Cotter, M.A. and Muneer, A. (2013) Pathophysiology of Diabetic Erectile Dysfunction: Potential Contribution of Vasa Nervorum and Advanced Glycation Endproducts. International Journal of Impotence Research, 25, 1-6. http://dx.doi.org/10.1038/ijir.2012.30
Ryan, J.G. and Gajra, J. (2012) Erectile Dysfunction and Its Association with Metabolic Syndrome and Endothelial Dysfunction among Patients with Type 2 Diabetes Mellitus. Journal of Diabetes and Its Complications, 26, 141-147.
Naka, K.K., Papathanassiou, K., Bechlioulis, A., Kazakos, N., Pappas, K., Tigas, S., Makriyiannis, D., Tsatsoulis, A. and Michalis, L.K. (2012) Determinants of Vascular Functions in Patients with Type 2 Diabetes. Cardiovascular Diabetology, 11, 127. http://dx.doi.org/10.1186/1475-2840-11-127
Shen, Y., Weng, S., Wang, J. and Tien, K. (2014) Erectile Dysfunction and Risk of End Stage Renal Disease Requiring Dialysis: A Nationwide Population-Based Study. PLoS ONE, 9, e102055.